KNSA Kiniksa Pharmaceuticals Ltd
- Stocks
- Healthcare
- NASDAQ: KNSA
Price (delayed)
$32.15
Market cap
$2.38B
P/E Ratio
535.83
Dividend/share
N/A
EPS
$0.06
Enterprise value
$2.2B
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's portfolio of
Highlights
KNSA's net income has surged by 147% year-on-year and by 128% since the previous quarter
The EPS has surged by 140% year-on-year and by 125% since the previous quarter
KNSA's quick ratio is down by 9% QoQ
KNSA's gross margin is down by 2.1% YoY
Key stats
What are the main financial stats of KNSA
Market
Valuations
Earnings
Shares outstanding
74.11M
Market cap
$2.38B
Enterprise value
$2.2B
Price to earnings (P/E)
535.83
Price to book (P/B)
4.74
Price to sales (P/S)
4.46
EV/EBIT
154.28
EV/EBITDA
115.54
EV/Sales
4.16
Revenue
$529.33M
Gross profit
$454.86M
Operating income
$4.48M
Net income
$4.79M
EBIT
$14.26M
EBITDA
$19.04M
Free cash flow
$66.49M
Per share
Balance sheet
Liquidity
EPS
$0.06
EPS diluted
$0.04
Free cash flow per share
$0.91
Book value per share
$6.78
Revenue per share
$7.21
TBVPS
$8.79
Total assets
$661.15M
Total liabilities
$166.14M
Debt
$9.77M
Equity
$495.01M
Working capital
$302.48M
Debt to equity
0.02
Current ratio
3.57
Quick ratio
2.88
Net debt/EBITDA
-9.57
Margins
Efficiency
Dividend
EBITDA margin
3.6%
Gross margin
85.9%
Net margin
0.9%
Operating margin
0.8%
Return on assets
0.8%
Return on equity
1%
Return on invested capital
4.3%
Return on capital employed
2.6%
Return on sales
2.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KNSA stock price
How has the Kiniksa Pharmaceuticals stock price performed over time
Intraday
-2.9%
1 week
0.53%
1 month
18.16%
1 year
29.79%
YTD
62.54%
QTD
16.19%
Financial performance
How have Kiniksa Pharmaceuticals's revenue and profit performed over time
Revenue
$529.33M
Gross profit
$454.86M
Operating income
$4.48M
Net income
$4.79M
Gross margin
85.9%
Net margin
0.9%
KNSA's net income has surged by 147% year-on-year and by 128% since the previous quarter
The net margin has surged by 130% year-on-year and by 126% since the previous quarter
KNSA's operating income has surged by 128% since the previous quarter and by 116% year-on-year
KNSA's operating margin has surged by 124% since the previous quarter and by 110% year-on-year
Price vs fundamentals
How does KNSA's price correlate with its fundamentals
Growth
What is Kiniksa Pharmaceuticals's growth rate over time
Valuation
What is Kiniksa Pharmaceuticals stock price valuation
P/E
535.83
P/B
4.74
P/S
4.46
EV/EBIT
154.28
EV/EBITDA
115.54
EV/Sales
4.16
The EPS has surged by 140% year-on-year and by 125% since the previous quarter
KNSA's price to book (P/B) is 39% higher than its 5-year quarterly average of 3.4 and 28% higher than its last 4 quarters average of 3.7
Kiniksa Pharmaceuticals's equity has increased by 14% YoY and by 8% from the previous quarter
The stock's price to sales (P/S) is 70% less than its 5-year quarterly average of 14.8 but 17% more than its last 4 quarters average of 3.8
Kiniksa Pharmaceuticals's revenue has surged by 56% YoY and by 10% QoQ
Efficiency
How efficient is Kiniksa Pharmaceuticals business performance
KNSA's ROIC has soared by 178% YoY
The return on sales has surged by 151% year-on-year
Kiniksa Pharmaceuticals's return on equity has surged by 142% YoY and by 126% QoQ
Kiniksa Pharmaceuticals's return on assets has surged by 140% YoY and by 127% QoQ
Dividends
What is KNSA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KNSA.
Financial health
How did Kiniksa Pharmaceuticals financials performed over time
KNSA's total liabilities has surged by 55% year-on-year and by 17% since the previous quarter
The company's total assets rose by 22% YoY and by 10% QoQ
The debt is 98% smaller than the equity
The debt to equity has contracted by 33% YoY
Kiniksa Pharmaceuticals's equity has increased by 14% YoY and by 8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.